Sort
51,593 grants matching “hepatitis”
Revolutionary Eilat-based Chikungunya Vaccine Vector
$825,842Tian Wang · University Of Texas Med Br Galveston · R01 · FY2021 · AI
Xenobiotic metabolism, cancer chemoprevention and cancer biomarkers
$825,656Frank J Gonzalez · Division Of Basic Sciences - Nci · ZIA · FY2019 · CA
Biorepository for Genomic Medicine in diverse Communities
$825,389Erwin P. Bottinger · Icahn School Of Medicine At Mount Sinai · U01 · FY2012 · HG
Dynamics of antigen specific B and Tfh responses during acute and chronic HCV
$825,277Arash Grakoui · Emory University · R01 · FY2018 · AI
HEPATITIS C VIRUS REPLICATION AND LIVER INJURY
$825,248University Of Washington · U19 · FY2004 · AI
The role of cancer stem cells in liver cancer heterogeneity and subtypes
$825,166Xin Wang · Division Of Basic Sciences - Nci · ZIA · FY2014 · CA
Molecular signatures for liver cancer diagnosis and treatment stratification
$825,166Xin Wang · Division Of Basic Sciences - Nci · ZIA · FY2014 · CA
A Randomized Phase I Clinical Trial of HydroVax-YFV, a Novel Inativated Yellow Fever Vaccine
$825,048Ian James Amanna · Najit Technologies, Inc. · U44 · FY2023 · AI
MBRS-SCORE Program at UPR-Medical Sciences Campus
$825,000Walter I Silva · University Of Puerto Rico Med Sciences · S06 · FY2008 · GM
Immune Control and Immune Evasion during Acute Hepatitis C Virus Infection
$824,922Georg Michael Lauer · Massachusetts General Hospital · U19 · FY2007 · AI
Pharmacogenomics and Systems Pharmacology Approaches to Toxicity, Tolerability, and Comorbidities Associated with Modern Antiretroviral Therapies
$824,847Inga Peter · Icahn School Of Medicine At Mount Sinai · R01 · FY2020 · HG
Alimentary Tract Lipids in Health and Disease
$824,846Martin Conrad Carey · Brigham And Women'S Hospital · R37 · FY2013 · DK
MASLD protection by STAT5-regulated transcription factors
$824,655Rhonda D. Kineman · University Of Illinois At Chicago · R01 · FY2025 · DK
Mitigating the Outcomes Associated with the Injection Drug Use Epidemic in Southern Appalachia
$824,628William A Zule · Research Triangle Institute · UH3 · FY2019 · DA
Pathogenesis of Hepatitis B Virus in Transgenic Mice
$824,562Francis Vincent Chisari · Scripps Research Institute, The · R01 · FY2010 · CA
Immunology of Acute and Chronic Viral Hepatitis
$824,239Barbara Rehermann · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2022 · DK
Role of the innate immune defenses in viral infections
$824,239Barbara Rehermann · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2022 · DK
Development of a novel drug candidate that inhibits hepatitis B virus covalently
$824,100Haitao Guo · Drexel University · R01 · FY2011 · AI
HCV Transmission among Young IDUs in NYC
$824,042Brian R. Edlin · Suny Downstate Medical Center · R01 · FY2009 · DA
An Interdisciplinary Approach to HIV and Other Infectious Diseases of Drug Users
$824,028Sherry Deren · New York University · P30 · FY2012 · DA
Dietary treatment of Glucose Transporter Type 1 Deficiency (G1D)
$824,012Juan M. Pascual · Ut Southwestern Medical Center · R01 · FY2016 · NS
Apolipoprotein C3-loading of apolipoprotein B100 lipoproteins and cardiovascular disease in patients with type 1 diabetes
$823,854Jay W Heinecke · University Of Washington · R01 · FY2023 · HL
Apolipoprotein C3-loading of apolipoprotein B100 lipoproteins and cardiovascular disease in patients with type 1 diabetes
$823,854Jay W Heinecke · University Of Washington · R01 · FY2024 · HL
Pharmacogenomics and Systems Pharmacology Approaches to Toxicity, Tolerability, and Comorbidities Associated with Modern Antiretroviral Therapies
$823,609Inga Peter · Icahn School Of Medicine At Mount Sinai · R01 · FY2022 · HG
Pharmacogenomics and Systems Pharmacology Approaches to Toxicity, Tolerability, and Comorbidities Associated with Modern Antiretroviral Therapies
$823,490Inga Peter · Icahn School Of Medicine At Mount Sinai · R01 · FY2023 · HG